Deals review
- Deals review
- Deal details
Cytoclonal secures rights to bacterial drug resistance target
In order to access this content you must be logged in and have a subscription to Pharmalicensing Intelligence.
Pharmalicensing Intelligence is a one-stop environment for time-conscious executives. Keeping you abreast of the latest developments in the life sciences industry, saving you time and money when you need it most.
Related deals
Callisto and Array BioPharma announce drug discovery collaboration
Dyax acquires rights related to inflammation target
Tercica Licenses Patent Rights to rhIGF-1 From Fujisawa in Extreme Insulin Resistance
Dyax acquires exclusive rights related to angiogenesis target
Study demonstrates benefits of HIV drug resistance testing
Keygene and Wageningen UR sign a licensing agreement and strengthen their collaboration
Cytoclonal and Bristol-Myers Squibb sign R&D agreement extension
Related categories
- Therapeutic target
- Infectious diseases
- Industry sector
- Pharmaceutical
More deals
Latest deals
- Biovator and BASF sign technology development agreement
- Agfa HealthCare signs four-year agreement with Chinese partners for distribution of radiography solutions, potentially worth 500 million US dollar
- Omnicare Announces Acquisition of Continuing Care Rx
- Nabi Biopharmaceuticals Announces Long-Term Manufacturing Agreement With Diosynth RTP
- GreenVax Selects Xcellerex XDR Single-Use Bioreactors for New Vaccine and Biotherapeutics Program
Most viewed deals
- Recommended acquisition of Acambis plc ("Acambis") by Sanofi Pasteur Holding ("Sanofi Pasteur") by way of scheme of arrangement Posting of Scheme Document
- Omnicare Announces Acquisition of Continuing Care Rx
- Bayer CropScience and Janssen PMP conclude research agreement:
- Nabi Biopharmaceuticals Announces Long-Term Manufacturing Agreement With Diosynth RTP
- Biovator and BASF sign technology development agreement
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us